Business
Grant Success for Glioblastoma studies
Grant Success for Glioblastoma studies.
About this update from Theracryf Plc
[{"type":"text","content":"\n\n \nEvgen Pharma plc\n(\"Evgen\" or \"the Company\" or \"the Group\")\n \nEvgen receives notification of grant success in the Netherlands\nfor Glioblastoma Pre-clinical and Clinical Studies\n \nGrant provides non-dilutive funding for SFX-01 in glioblastoma\n \n \n19 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the Company's collaborator at The Erasmus University Medical Center, Rotterdam, NL has received a successful notice of a grant for Investigator Sponsored pre-clinical and clinical studies of SFX-01 in glioblastoma. The grant was awarded by KWF Dutch Cancer Society.\n \nThe studies funded by the grant will cover use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS) window-of-opportunity study in glioblastoma patients, to establish presence of the drug in human brain tumours and engagement with relevant molecular targets in excised tumour tissue. The work will be conducted by, in the laboratory and clinic of, Dr Marjolein Geurts, neurologist at Erasmus MC Cancer Institute, Rotterdam, the Netherlands.\n \nDr Huw Jones, CEO of Evgen Pharma said:\n \n\"We announced earlier this year that our glioblastoma programme would be conducted as an ISS with non-dilutive funding. This award means that we remain on schedule to deliver this study in close collaboration with Dr Geurts. Congratulations to her and the Evgen team who compiled the grant application. The non-dilutive funding enables us to continue to preserve our capital and maintain our cash runway to the end of 2024 whilst continuing to generate valuable data on SFX-01. If the ISS and subsequent clinical trials succeed, SFX-01 will represent a novel and well tolerated option for patients with this devastating disease.\"\n \n \nEnquiries:\n\n\n\nEvgen Pharma plc\nDr Huw Jones, CEO \nRichard Moulson, CFO \n\n\nTel: +44 207 457 2020 [email protected]\n\n\n\n\nFinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance)\nAlice Lane/Nigel Birks (ECM)\n\n\nTel: +44 20 7220 0500\n\n\n\n\nInstinctif Partners\nMelanie Toyne-Sewell / Rozi Morris / Adam Loudon\n\n\nTel: +44 207 457 2020\[email protected]\...